Nextdoor Got Me… But Not the Way They Think

Nextdoor and #NiravTolia got me.

The dark side is strong with you.

For months, I’ve been publishing my original articles on https://NielFlamm.com/blog, then sharing either the full article or a shortened version across multiple social media platforms.

One platform I generally skip is Nextdoor. Based on my experiences, I don’t have much confidence that posts critical of the company would survive moderation for long. I also recently resubscribed under a "verified" address/name combo that isn't my own for an experiment.

Then it hit me.

By reposting my commentary on X, including replies involving Sarah Leary, I was helping generate engagement on a platform that offers monetization opportunities through programs like revenue sharing, creator subscriptions, and other creator incentives.

So…

You got me.

Going forward, I’ll be a little more strategic about where I distribute my content and where I send my clicks.

If I’m going to spend time creating articles, videos, and commentary, I’d rather direct readers to my own platform than contribute engagement that may ultimately benefit the very people I’m questioning.

And who knows…

Maybe I won’t be the one helping fund a 2027 Rolls-Royce Ghost. 😄

All kidding aside, this has been a good reminder that attention has value. Every click, view, comment, and share contributes to someone’s ecosystem.

I’m simply choosing to be more intentional about where mine goes.

Be a part of the discussion on NielFlamm.com.

Nextdoor, Pharma, and the Lowest-Hanging Fruit

I came across a pharmaceutical marketing benchmark survey that mentions Nextdoor as part of the media landscape.

One thing stood out to me: Nextdoor didn't even lead the study. It was simply referenced as another channel.

And, by the way, this is now Day #3 since I requested the complete insurance study from Jacob Chavis. Still no report. Still no acknowledgment. At this point, I'm not surprised.

Back to the survey.

My first reaction was that this feels like picking the lowest-hanging fruit.

A census tells us where populations are aging. Local demographic data shows where seniors live. It's hardly groundbreaking to conclude that neighborhoods with older residents will have greater demand for medications that improve quality of life.

Any competent regional pharmaceutical sales team already knows which physicians are prescribing what, which pharmacies are dispensing it, and where the opportunities exist. Compensation plans, quotas, bonuses, and territory strategies have relied on those metrics for years.

And if AI is truly the revolutionary force that Nextdoor leadership frequently promotes, why not simply overlay prescribing trends, demographic data, and ZIP code maps? The opportunities would become obvious without another marketing survey.

My larger concern is perception.

After watching the outstanding miniseries Dopesick, which explored the devastating impact of Purdue Pharma, OxyContin, and the Sackler family's pursuit of profit, I find it disappointing to see neighborhood platforms associated with pharmaceutical marketing studies without acknowledging the broader societal consequences that can accompany profit-driven healthcare initiatives.

Healthcare is essential. Medications save lives.

But when marketing becomes the primary focus without equal discussion of responsibility, history reminds us that communities can pay a heavy price.

In other news, NXDR is up today, but so is much of the broader market. I'm still watching to see whether the recent momentum holds or whether the bottom eventually falls out.

These are my personal opinions and observations and should not be interpreted as investment or medical advice.